Cargando…
5613260 A PHASE -- IIA-IIB, OPEN LABEL, SINGLE CENTER TRIAL TO STUDY SAFETY, TOLERABILITY AND EFFICACY OF MEMANTINE AS SUPPORTIVE LONG-TERM TREATMENT OF SICKLE CELL PATIENTS: TRIAL DESIGN AND ENROLLMENT
Autores principales: | Levin, C.L., Koren, A.K., Peretz, S.S.P., Livshits, L.L., Makhro, A.M., Bogdanova, A.B., Gassmann, M.G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10112626/ http://dx.doi.org/10.1097/01.HS9.0000928448.56489.99 |
Ejemplares similares
-
PB2222: THE PROTECTIVE EFFECT OF THE SPLEEN IN SICKLE CELL PATIENTS. A COMPARATIVE STUDY BETWEEN PATIENTS WITH ASPLENIA AND HYPERSPLENISM.
por: Peretz, S., et al.
Publicado: (2022) -
The protective effect of the spleen in sickle cell patients. A comparative study between patients with asplenia/hyposplenism and hypersplenism
por: Peretz, Sari, et al.
Publicado: (2022) -
MEMSID: Results From a Phase 2 Pilot Study on Memantine Treatment for Sickle Cell Disease
por: Hegemann, Inga, et al.
Publicado: (2020) -
Back to the “Gold Standard”: How Precise is Hematocrit Detection Today?
por: Livshits, Leonid, et al.
Publicado: (2022) -
Memantine Use and Cognitive Decline in Huntington's Disease: An Enroll‐HD Study
por: Ogilvie, Amy C., et al.
Publicado: (2023)